Patient Hospitalized After Receiving Intellia's CRISPR Therapy Dies, Prompting FDA Hold on Trials on November 07, 2025 Amyloidosis Clinical Trials Comorbidity CRISPR therapy Intellia Liver nex-z nexiguran ziclumeran patient death Phase III MAGNITUDE trial Toxicity aspects TTR wt Allele United States Food and Drug Administration +